In 2023, James F. Oliviero III earned $1.64M in total compensation at Checkpoint Therapeutics, Inc., including $635.58K salary and $720.00K in stock. Most recently sold 39,128 shares in Feb 2025. Has led Checkpoint Therapeutics, Inc. for over 10 years.
Compensation History
Annual executive compensation data for James F. Oliviero III, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$1.64M
Salary
$635.58K
Bonus
$0.00
Other
$286.01K
Salary
$635.58KBoard Justification
The compensation philosophy aligns with company performance, peer benchmarking, and retention strategies, focusing on long-term value creation for shareholders.
Bonus
$0.00Board Justification
Mr. Oliviero was eligible for an annual cash incentive equal to 50% of his base salary, with a maximum incentive of 75% based on company performance against pre-established goals, achieving 90% of target awards for 2023.
Other Compensation
$286.01KBoard Justification
Other compensation includes 401(k) contributions and other benefits.
Restricted Stock
Board Justification
The vested stock includes restricted stock units that were granted in previous years and vested in 2023, based on performance and time-based criteria.
Performance Metrics
Performance metrics include clinical and regulatory goals related to the company's lead product, with a target annual award based on achieving these goals.
James F. Oliviero III
CEO of Checkpoint Therapeutics, Inc.
Education
B.B.A. in Finance with Highest Distinction from Emory University’s Goizueta Business School
Field of Expertise
Finance & Banking - Finance
Sector of Economy
Healthcare
Born
January 1, 1976 - 49 years ago
CEO of Checkpoint Therapeutics, Inc. for
10 years 2 months (Oct 2015 - Present)
Previous Experience
Chief Financial Officer at Keryx Biopharmaceuticals, Inc.
Holdings
Track James F. Oliviero III's stock holdings and portfolio value over time.
Insider Trading
James F. Oliviero III's recent stock transactions, purchases, and sales filed with the SEC.
Rivals
Compare James F. Oliviero III with competitor CEOs and industry peers.